Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020068896 - METHOD AND SYSTEM FOR DETERMINING MICROSATELLITE INSTABILITY

Publication Number WO/2020/068896
Publication Date 02.04.2020
International Application No. PCT/US2019/052822
International Filing Date 25.09.2019
IPC
A61K 38/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
02Peptides of undefined number of amino acids; Derivatives thereof
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 7/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
06having 5 to 11 amino acids
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 16/30 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
CPC
A61K 38/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
02Peptides of undefined number of amino acids; Derivatives thereof
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Applicants
  • ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY [US]/[US]
Inventors
  • JOHNSTON, Stephen, Albert
  • STAFFORD, Phillip
  • ZHANG, Jian
  • SHEN, Luhui
Agents
  • BRANDLEY, Karri, Kuenzli
Priority Data
62/736,31425.09.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD AND SYSTEM FOR DETERMINING MICROSATELLITE INSTABILITY
(FR) MÉTHODE ET SYSTÈME DE DÉTERMINATION D'INSTABILITÉ MICROSATELLITE
Abstract
(EN)
Disclosed herein are methods and systems for determining microsatellite instability. In some embodiments, the disclosed methods and systems are used for determining whether a cancer patient has high microsatellite instability (MSI-H). MSI-H patients have remarkably good responses to immunotherapy, such as checkpoint inhibitors immunotherapy. Therefore, the disclosed methods and systems can be used for identifying MSI-H and thus, patients as candidates for immunotherapy. In turn, the disclosed methods and systems can be used to predict responsiveness to immunotherapy. In some embodiments, the methods further include providing an immunotherapy to the MSI-H patient. Also disclosed are vaccines and compositions.
(FR)
L'invention concerne des méthodes et des systèmes permettant de déterminer une instabilité microsatellite. Dans certains modes de réalisation, les méthodes et systèmes de l'invention sont utilisés pour déterminer si un patient cancéreux présente une instabilité microsatellite élevée (MSI-H). Les patients MSI-H ont des réponses remarquablement bonnes à l'immunothérapie, telle que l'immunothérapie d'inhibiteurs de points de contrôle. Par conséquent, les méthodes et systèmes de l'invention peuvent être utilisés pour identifier des MSI-H et, par conséquent, des patients en tant que candidats à une immunothérapie. Les méthodes et les systèmes de l'invention peuvent en retour être utilisés pour prédire la réactivité à une immunothérapie. Dans certains modes de réalisation, les méthodes comprennent en outre la fourniture d'une immunothérapie au patient MSI-H. L'invention concerne en outre des vaccins et des compositions.
Latest bibliographic data on file with the International Bureau